Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

Gilead reported Q2 Biktarvy sales of ~$3.77B, up 6.9% YoY and 12.2% QoQ, signaling momentum in its core HIV franchise. In addition, Livdelzi revenue rose to $167M, up 114.1% YoY, suggesting accelerating contribution from the PPARδ pipeline. Overall results point to growing near-term drivers, though headline figures are not yet at a blockbuster scale.

Analysis

The key signal is not the quarter itself, but that GILD is still compounding its core cash engine while the market has been pricing it like a slow decay story. Sustained HIV franchise strength matters because it preserves the company’s ability to self-fund R&D and buybacks, which can support a higher terminal multiple if investors start believing the earnings base is flatter for longer than expected.

The more interesting second-order effect is that Livdelzi’s ramp is evidence of commercial optionality outside HIV, which reduces single-portfolio risk and makes GILD less dependent on any one regimen or patent clock. If this trajectory continues for 1-3 quarters, it should pressure smaller liver-disease names such as ICPT by tightening access, payer attention, and specialist share, while also improving GILD’s bargaining position across its specialty pipeline.

Contrarian risk: the market may be extrapolating too much from a clean quarter before durability is proven. The thesis weakens if Biktarvy growth slips back below mid-single digits YoY or if Livdelzi does not sustain sequential uptake after launch inventory normalizes; that would keep GILD stuck as a cash cow rather than a re-rating story. Over 6-18 months, the real upside comes from multiple expansion on reduced patent-overhang anxiety, not from this quarter’s absolute revenue delta.

Key Decisions for Investors

• Long GILD on 2-3% pullbacks or ahead of the next print; 3-6 month horizon. Risk/reward favors a low-to-mid-teens total return if the market starts pricing in a more durable earnings base, with downside limited by cash generation and buyback support.
• Pair trade: long GILD / short XBI for the next 1-2 quarters. This isolates self-funded cash flow and execution quality versus a basket still exposed to financing risk; the spread should work if investors keep preferring profitable biopharma over speculative biotech.
• Set an alert on Biktarvy growth and Livdelzi sequential revenue into the next 1-2 quarters. If Biktarvy falls below 5% YoY or Livdelzi stalls, reduce exposure; if both stay strong, add to the long and consider a 6-12 month call-spread for convexity.